 During treatment period, patients will be treated with bortezomib, fludarabine and cyclophosphamide in a 28-day cycle. Patients achieve complete response CR or partial response PR can receive up to six cycles of VF C treatment, while those continue stable disease SD will be stopped after 4-cycle treatment and those with progressive disease PD will also be stopped after 2-cycle treatment. Due to adverse events, patients may receive reductions or deviate from the intended dose and duration of VF C treatment. These adjustments must be in accordance with the regulations in the protocol about the dose and time adjustment. 